Stay updated with breaking news from Longitudinal Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual
Purpose: This paper argues for the benefits to international business (IB) of taking a much longer view at the engagement by multinational enterprises (MNEs) with host locations. Design/methodology/approach: The authors showcase a project tracking the engagement by MNEs with Australia over the past two centuries. Extensive archival work has been undertaken to identify and document modes of entry, home countries, industries, operational modes and company types among the MNEs operating in Australia. The authors also describe the shifting nature of Australia as a host location. Findings: The auth...
2019 University of Pennsylvania/Children’s Hospital of Philadelphia’s lung-bone marrow chip.Science fiction or reality? Before traveling to Mars, NASA needs
In a recent study published in the journal Emerging Infectious Diseases, researchers analyzed and compared pre‒ and post‒COVID-19 diagnostic codes to identify symptoms that had higher encounter incidence in the post‒COVID-19 period as sequelae. COVID-19 sequelae and future emerging diseases can be generated and monitored using this method.
- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib